Text Size
Donate

New Drug Rhopressa Now Available for Open-Angle Glaucoma

Rhopressa 0.02% is a novel once-daily eye drop for lowering elevated intraocular pressure.

Aerie Pharmaceuticals announced the launch of Rhopressa (netarsudil ophthalmic solution) 0.02%, a novel eye drop indicated for lowering elevated intraocular pressure in patients with glaucoma and ocular hypertension.

Rhopressa is a rho kinase inhibitor that was approved by the Food and Drug Administration (FDA) in December 2017. The approval was based on results from 3 randomized trials which found that Rhopressa was associated with a reduction in intraocular pressure of up to 5mmHg.

Additionally, the results showed that for those with a baseline intraocular pressure <25mmHg, reductions were similar between groups treated with Rhopressa 0.02% dosed once daily and those treated with timolol 0.5% dosed twice daily.

Rhopressa ophthalmic solution contains 0.2mg/mL of netarsudil and is available as a 2.5mL fill in a 4mL container.

"Formulary contracts for commercial insurance coverage in 2018 and Medicare Part D program coverage beginning in 2019 are in the final stages of being executed," said Vicente Anido, Jr., PhD, Chairman and Chief Executive Officer. "In addition, through the availability of a co-pay savings card program, all patients covered by commercial insurance will have immediate access to Rhopressa. Aerie has also proactively engaged the major e-prescribing platforms to ensure physicians are able to prescribe Rhopressa electronically for their patients."

More information is available at rhopressa.com

Last reviewed on May 11, 2018

Was this helpful? Yes No